Le Lézard
Classified in: Health
Subjects: EXE, POL

Information Update - Cord blood banked at the Cord Blood Bank of Canada can be used only by the donor


OTTAWA, Oct. 17, 2017 /CNW/ -

Issue
Following recent complaints, Health Canada initiated a review to verify whether the Cord Blood Bank of Canada, a private cord blood bank, was in compliance with the acts and regulations that apply to cord blood in Canada.

Health Canada's review revealed that the Client Service Agreement published on the company's website suggested that cord blood banked on behalf of clients could be donated to another individual upon termination of the agreement. This is known as allogeneic use. The document also contained statements that could lead clients to believe that the company is a registered establishment and therefore subject to Health Canada oversight under the Safety of Human Cells, Tissues and Organs for Transplantation Regulations (CTO Regulations).

As of January 1, 2016, the Cord Blood Bank of Canada is no longer a registered establishment under the CTO Regulations and as such, cannot bank cord blood for allogeneic use. It can bank cord blood for use only by the donor; known as autologous use.

At Health Canada's request, the company has clarified on its website that only autologous use is permitted. Health Canada also requested that the Cord Blood Bank of Canada notify its clients that only autologous use is permitted. Through its correspondence with the company, Health Canada has not been able to verify that clients have been adequately informed. Therefore, Health Canada is advising Canadians that the Cord Blood Bank of Canada can store cord blood for use only by the donor.

What you should do

Background
The primary aim of the CTO Regulations is to minimize the potential health risks transmitted from donors to recipients (allogeneic donations) of human cells, tissues or organs. Establishments that process, bank or distribute cord blood for allogeneic purposes are required to hold a Registration and to demonstrate that the products they handle have been processed according to health and safety standards. In autologous donations, the recipient is also the donor. As such, there is no risk of transmission of an infectious disease from the donor to the recipient, which is why autologous donations are excluded from the CTO Regulations.

Health Canada inspected the Cord Blood Bank of Canada in 2015 to assess compliance with the CTO Regulations. At that time, the Cord Blood Bank of Canada was registered under the CTO Regulations for processing and banking cord blood for both autologous and allogeneic use. The Department made several observations and the company received a non-compliant rating. As a result of the lack of satisfactory responses to address these observations, Health Canada did not renew the company's Registration, which meant that allogeneic use was no longer permitted. The company provided written confirmation that it was operating for autologous use only, to which the CTO Regulations do not apply.  

In 2016, Health Canada requested that the Cord Blood Bank of Canada modify its website to remove reference to allogeneic use, and requested further actions again in August 2017.

In the future, if the Cord Blood Bank of Canada would like to release banked cord blood for allogeneic use, it would need to apply for a new Registration and demonstrate that the cord blood is processed in accordance with the CTO Regulations. In the meantime, the Cord Blood Bank of Canada, like all banks that store cord blood (whether for allogeneic or autologous use), must meet requirements under the Food and Drugs Act.

Stay connected with Health Canada and receive the latest advisories and product recalls using social media tools.

Également disponible en français

 

SOURCE Health Canada


These press releases may also interest you

at 14:20
The global gastroesophageal reflux disease (GERD) market  size is estimated to grow by USD 879.8 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  3.2%  during the forecast period.  Rising geriatric...

at 12:48
Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distribution agreement with Ascendis Pharma A/S ("Ascendis"), a global biopharmaceutical company headquartered in Copenhagen, Denmark. Under the terms of...

at 12:36
Imperial Tobacco Canada Limited ("ITCAN") has officially submitted its feedback to Health Canada regarding the proposed Ministerial Order on nicotine replacement therapy products (NRTs). ITCAN strongly believes that NRTs, especially innovative...

at 12:20
The "Regenerative Medicine Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Regenerative Medicine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented...

at 12:10
The "Diagnostic Imaging Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering. Diagnostic Imaging Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to...

at 12:05
King Faisal Specialist Hospital & Research Centre (KFSH&RC) has achieved a significant milestone in its Robotic Cardiac Surgery Program, which was initiated in February 2019. Within its first year, the program performed 105 cardiac procedures. As of...



News published on and distributed by: